Skip to main content
. 2023 Feb 13;83(8):1214–1233. doi: 10.1158/0008-5472.CAN-22-1769

Figure 6.

Figure 6. Expression of myeloma cell–associated therapeutic targets in relation to clinical features. A, Heat map showing normalized expression of candidate targets across longitudinal samples. Different disease stages are annotated in different colors on the right of the heat map. B, UMAP showing plasma cells from samples taken at two different stages of patient 56203, colored by seurat clusters. C, Heat map showing normalized expression of candidate targets across three plasma populations in patient 56203. Genes detected in fewer than 5 cells are not considered during normalization and thus were not included in the heat map. D, UMAP showing plasma cells from samples taken at six different time points of patient 27522, colored by sample. E, Expression of typical myeloma cell–associated therapeutic targets reveals diverse and dynamic change of gene expression along the disease progression in the same patient. F, UMAP showing plasma cells from samples in MMRF Immune Atlas Pilot study, colored by patient. G, UMAP showing plasma cells from samples in MMRF Immune Atlas Pilot study, colored by patients’ progression features. H, Violin plots showing expression of TNFRSF13C and RASGRP3 are significantly elevated in rapid progressors compared with nonprogressors (P < 0.05).

Expression of myeloma cell–associated therapeutic targets in relation to clinical features. A, Heat map showing normalized expression of candidate targets across longitudinal samples. Different disease stages are annotated in different colors on the right of the heat map. B, UMAP showing plasma cells from samples taken at two different stages of patient 56203, colored by seurat clusters. C, Heat map showing normalized expression of candidate targets across three plasma populations in patient 56203. Genes detected in fewer than five cells were not considered during normalization and thus were not included in the heat map. D, UMAP showing plasma cells from samples taken at six different time points of patient 27522, colored by sample. E, Expression of typical myeloma cell–associated therapeutic targets reveals diverse and dynamic change of gene expression along the disease progression in the same patient. F, UMAP showing plasma cells from samples in MMRF Immune Atlas Pilot study, colored by patient. G, UMAP showing plasma cells from samples in MMRF Immune Atlas Pilot study, colored by patients’ progression features. H, Violin plots showing expression of TNFRSF13C and RASGRP3 is significantly elevated in rapid progressors compared with nonprogressors (P < 0.05).